07:00 , Mar 10, 2014 |  BioCentury  |  Strategy

Abiding its time

Abide Therapeutics Inc.'s option deal with Celgene Corp. gives it several years to validate its serine hydrolase platform. Should Celgene opt to license ex-U.S. rights to Abide's lead inflammation programs rather than buy the company...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Company News

Abide Therapeutics, Celgene deal

Celgene paid Abide $50 million up front in exchange for an exclusive option to acquire Abide for undisclosed terms. Celgene gained an undisclosed equity stake in Abide, and existing investor Cardinal Partners made a $10...
08:00 , Mar 3, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Anika Therapeutics Inc. (NASDAQ:ANIK) rose $11.43 (33%) to $45.90 on Wednesday after saying FDA approved Monovisc to treat osteoarthritis of the knee. Monovisc is a single injection that delivers hyaluronic acid from a non-animal...
01:10 , Mar 1, 2014 |  BC Extra  |  Top Story

Abide grants Celgene options

Celgene Corp. (NASDAQ:CELG) paid Abide Therapeutics Inc. (Princeton, N.J.) $50 million up front in exchange for an exclusive option to acquire Abide for undisclosed terms. Celgene gained an undisclosed equity stake in Abide, and existing...